TrialJCO precision oncology2024

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial.

Joyce F Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.